Trial Profile
A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Jan 2024
Price :
$35
*
At a glance
- Drugs Parsaclisib (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- Acronyms CITADEL-205
- Sponsors Incyte Corporation
- 19 Jan 2024 This study has been completed in Denmark.
- 13 Jul 2023 This study has been completed in Belgium, according to European Clinical Trials Database.
- 16 Jun 2023 Planned End Date changed from 31 Mar 2023 to 30 Apr 2024.